These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients. Tiong HY; Flechner SM; Zhou L; Wee A; Mastroianni B; Savas K; Goldfarb D; Derweesh I; Modlin C Transplantation; 2009 Jan; 87(2):296-302. PubMed ID: 19155988 [TBL] [Abstract][Full Text] [Related]
6. Similar early complication rate in simultaneous pancreas and kidney recipients on tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus immunosuppressive regimens. Girman P; Lipar K; Koznarova R; Boucek P; Kriz J; Kocik M; Havrdova T; Adamec M; Saudek F Transplant Proc; 2010; 42(6):1999-2002. PubMed ID: 20692391 [TBL] [Abstract][Full Text] [Related]
7. Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy. Rogers CC; Hanaway M; Alloway RR; Alexander JW; Boardman RE; Trofe J; Gupta M; Merchen T; Buell JF; Cardi M; Roy-Chaudhury P; Succop P; Woodle ES Transplant Proc; 2005 Mar; 37(2):795-7. PubMed ID: 15848534 [TBL] [Abstract][Full Text] [Related]
8. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S; Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205 [TBL] [Abstract][Full Text] [Related]
9. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781 [TBL] [Abstract][Full Text] [Related]
10. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Kuppahally S; Al-Khaldi A; Weisshaar D; Valantine HA; Oyer P; Robbins RC; Hunt SA Am J Transplant; 2006 May; 6(5 Pt 1):986-92. PubMed ID: 16611334 [TBL] [Abstract][Full Text] [Related]
11. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Flechner SM; Feng J; Mastroianni B; Savas K; Arnovitz J; Moneim H; Modlin CS; Goldfarb D; Cook DJ; Novick AC Transplantation; 2005 Apr; 79(8):926-34. PubMed ID: 15849545 [TBL] [Abstract][Full Text] [Related]
12. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Anil Kumar MS; Heifets M; Fyfe B; Saaed MI; Moritz MJ; Parikh MH; Kumar A Transplantation; 2005 Sep; 80(6):807-14. PubMed ID: 16210969 [TBL] [Abstract][Full Text] [Related]
13. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Mendez R; Gonwa T; Yang HC; Weinstein S; Jensik S; Steinberg S; Transplantation; 2005 Aug; 80(3):303-9. PubMed ID: 16082323 [TBL] [Abstract][Full Text] [Related]
14. Impact of mycophenolate mofetil on wound complications and lymphoceles after kidney transplantation. Lopau K; Syamken K; Rubenwolf P; Riedmiller H; Wanner C Kidney Blood Press Res; 2010; 33(1):52-9. PubMed ID: 20197687 [TBL] [Abstract][Full Text] [Related]
15. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989 [TBL] [Abstract][Full Text] [Related]
16. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149 [TBL] [Abstract][Full Text] [Related]
17. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Kobashigawa JA; Miller LW; Russell SD; Ewald GA; Zucker MJ; Goldberg LR; Eisen HJ; Salm K; Tolzman D; Gao J; Fitzsimmons W; First R; Am J Transplant; 2006 Jun; 6(6):1377-86. PubMed ID: 16686761 [TBL] [Abstract][Full Text] [Related]
18. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J Transplantation; 2004 Jan; 77(2):252-8. PubMed ID: 14742990 [TBL] [Abstract][Full Text] [Related]
19. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Chhabra D; Skaro AI; Leventhal JR; Dalal P; Shah G; Wang E; Gallon L Clin J Am Soc Nephrol; 2012 Mar; 7(3):504-12. PubMed ID: 22282478 [TBL] [Abstract][Full Text] [Related]
20. Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. Heilman RL; Younan K; Wadei HM; Mai ML; Reddy KS; Chakkera HA; Gonwa TA Transplantation; 2011 Oct; 92(7):767-73. PubMed ID: 21775930 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]